



## Customer Notification Letter

SF25050801  
May 08, 2025

**Product Line:** Molecular POCT

**Subject:** The Inclusivity of Pluslife Test Card for SARS-CoV-2 Variants Detection

To whom it may concern,

The Novel Coronavirus (SARS-CoV-2) is an RNA virus characterized by its high mutation rate. In response to the emergence of various variants of the Novel Coronavirus, Pluslife Biotech Co., Ltd. has re-analyzed the alignment results for the detection target regions of our SARS-CoV-2 Nucleic Acid Testing Card and SARS-CoV-2/Influenza A/Influenza B Nucleic Acid Test Card.

The results affirm that our test cards can accurately detect all reported variants, including those categorized as "Variants of Concern" (VOC) by the World Health Organization (WHO). Crucially, our tests exhibited no false-negative results and avoided off-target situations. The reported variants encompass a range of Novel Coronavirus variants as listed below, and this list is not exhaustive.

### Alpha

(B.1.1.7/Q.7);

### Beta

(B.1.351/B.1.351.2/B.1.351.3);

### Gamma

(P.1/P.1.1/P.1.2);

### Delta

(B.1.617.2/AY.1/AY.2/AY.3/AY.3.1/AY.4/AY.4.2/AY.5/AY.5.1/AY.5.2/AY.6/AY.7/AY.8/AY.9/AY.10/AY.25/AY.27/AY.30/AY.70/AY.74/AY.88/AY.107);

### Omicron

(B.1.1.529/ B.1.617.2/ BA.1/ BA.1.1/ BA.2/ BA.2.2/ BA.2.75/ BA.2.75.2/ BA.2.12/ BA.2.12.1/ BA.3/ BA.4/BA.4.6/BA.5/BA.5.2/BA.5.2.6/XE/BO.1.1/BF.7/BF.11/B0.1/BO.1.1/BN.1/CH.1.1/XBB/XBB.1.5/BB.1.5.1/XBB.1.6/XBB.1.16/XBB.2.3/XBB.1.9.1/XBB.1.9.2/BA.2.86/DN.1/JN.1(LP.8.1)/KP.2/KP.3/XE C) and the WHO VOI-labelled variants Eta (B.1.525), Theta (P.3), Iota (B.1.526), Kappa (B.1.617.1), Lambda (C.37), Mu (B.1.621/B.1.621.1), and the variants Epsilon (B.1.427/B.1.429), Zeta (P.2), XD, XF.

Pluslife Biotechnology Technical Support Team  
Customer Service Center  
May 08, 2025

